ANXA1 and inflammatory bowel disease: This hypothesis was also supported by Paula-Silva et al., who demonstrated that ANXA1 contributes to the restoration of intestinal homeostasis after TNF-α inhibition with infliximab (used in the treatment of IBD), constituting a potential biomarker of therapeutic efficacy [66].